Says is in interest of people
The committee constituted by the Madhya Pradesh government to prepare guidelines to regulate drug trials in the state has recommended restarting the trials.
The state government had put a ban on any new clinical trials in October last year following reports of unethical drug trials. The medical education department of the government had asked the committee to give recommendations on how to effectively regulate clinical trials. The committee submitted its report last month but did not suggest any punishment for those responsible for conducting unethical trials.
Meanwhile, reports of unethical clinical trials in Madhya Pradesh are pouring in. Around 233 mentally ill patients were subjected to clinical trials in Indore for checking efficacy of various drugs, including 42 patients for dapoxetine, a drug used to cure premature ejaculation. These trials were conducted by doctors of Mahatma Gandhi Medical College in private clinics between January 2008 and December 2010 after taking permission from independent ethics committee.
“The mental hospital, a branch of Mahatma Gandhi Medical College, has its own ethics committee. Then why the approval was taken from the independent ethics committee,” asks Rai. According to the guidelines of Indian Council of Medical Research, approval is taken from independent ethics committee only if the institution does not have its own ethics committee.
Abhay Paliwal, associate professor with the Mental Hospital at Indore who conducted some of these trials says, “We have not violated any norms, all of these trials were approved by the Drugs Controller General of India.”
In its recommendations, the state level committee has said that the state should open clinical trials as it is in the interest of people. Its recommendations broadly sum up what is already present in the schedule Y of Drugs and Cosmetics Act 1940 and Ethical guidelines for Biomedical Research on human participants. It also calls for making the trial drug available to the patient till it comes in the market. But public health experts argue they say the drug should be made available life long as after coming in the market it will be expensive for the patient to buy.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.